Literature DB >> 10950048

Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease.

A Schottelius1, S Wedel, R Weltrich, W Rohde, F Buttgereit, S Schreiber, H Lochs.   

Abstract

OBJECTIVE: Glucocorticoids are widely used in the treatment of inflammatory bowel disease (IBD). Up- and down-regulated expression of glucocorticoid receptors (GR) has been reported for different chronic inflammatory diseases. The aim of this study was to investigate the expression of GR and their apparent dissociation constant (Kd) in patients with IBD.
METHODS: Thirty-nine patients with IBD (22 with ulcerative colitis, 17 with Crohn's disease) and 35 normal controls were studied. Twenty-five patients did not receive steroids, 14 patients were treated with steroids. Peripheral blood mononuclear cells from patients and controls were isolated using the Ficoll-Hypaque gradient and a whole cell [3H]-dexamethasone binding assay and Scatchard plot analysis were performed to assess GR number and the apparent dissociation constant. Results were expressed as mean +/- standard deviation.
RESULTS: Normal controls showed an expression of 3,969 +/- 1,555 GR per cell with an apparent dissociation constant of 6.16 +/- 3.8 nmol/L. IBD patients without steroids had a significant increase both in the expression of GR per cell (6,401 +/- 2,344; p < 0.0001; Wilcoxon-Mann-Whitney test) and in the apparent dissociation constant (11.02 +/- 7.57 nmol/L; p = 0.006). Expression of GR in IBD patients was suppressed to normal levels under steroid treatment (4,594 +/- 2,237; p = 0.024), but Kd remained elevated (13.56 +/- 9.05 nmol/L). Plasma cortisol levels were not different between IBD patients and the control group.
CONCLUSIONS: Our data show a systemic increase in GR expression and a decrease in the affinity to the GR in IBD, in contrast to other inflammatory diseases such as rheumatoid arthritis and asthma. These changes point towards a systemic character of IBD, which might be considered in a decision between topical and systemic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950048     DOI: 10.1111/j.1572-0241.2000.02188.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

Review 1.  Clinical pharmacology of inflammatory bowel disease therapies.

Authors:  W J Sandborn; W A Faubion
Journal:  Curr Gastroenterol Rep       Date:  2000-12

2.  Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene.

Authors:  Katharine H Banner; Christophe Cattaneo; Jean-Loic Le Net; Aleksandar Popovic; David Collins; Jeremy D Gale
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

3.  Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease.

Authors:  Sung-Hoon Ahn; Yatrik M Shah; Junko Inoue; Keiichirou Morimura; Insook Kim; Sunhee Yim; Gilles Lambert; Reiko Kurotani; Kunio Nagashima; Frank J Gonzalez; Yusuke Inoue
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

4.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

Authors:  Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez
Journal:  Arch Ophthalmol       Date:  2009-09

5.  Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis.

Authors:  Hu Zhang; Qin Ouyang; Zhong-Hui Wen; Claudio Fiocchi; Wei-Ping Liu; Dai-Yun Chen; Feng-Yuan Li
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

6.  Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway.

Authors:  C M Spies; D H S Schaumann; T Berki; K Mayer; M Jakstadt; D Huscher; C Wunder; G-R Burmester; A Radbruch; R Lauster; A Scheffold; F Buttgereit
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

7.  A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.

Authors: 
Journal:  Ophthalmology       Date:  2008-07-26       Impact factor: 12.079

8.  Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus.

Authors:  Juan Du; Min Li; Denghai Zhang; Xiaoyan Zhu; Weiwei Zhang; Wei Gu; Yinglu Feng; Xiaofeng Zhai; Changquan Ling
Journal:  Arthritis Res Ther       Date:  2009-07-14       Impact factor: 5.156

9.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.

Authors:  Ingrid U Scott; Michael S Ip; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Clement K Chan; Victor H Gonzalez; Lawrence J Singerman; Michael Tolentino
Journal:  Arch Ophthalmol       Date:  2009-09

10.  Th2 cytokine-induced upregulation of 11beta-hydroxysteroid dehydrogenase-1 facilitates glucocorticoid suppression of proasthmatic airway smooth muscle function.

Authors:  Aihua Hu; Sumbul Fatma; Jing Cao; Judith S Grunstein; Gustavo Nino; Yael Grumbach; Michael M Grunstein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-27       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.